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Abstract 
Background: 
Radiation-induced skin reaction (RISR) is one of the most common and distressing 
side effects of radiotherapy in patients with cancer. It is featured with swelling, 
redness, itching, pain, breaks in skin, discomfort, and a burning sensation. There is 
a lack of convincing evidence supporting any single practice in the prevention or 
management of RISR. 
Methods/Designs: 
This double-blinded randomised controlled trial aims to investigate the effects of a 
natural oil-based emulsion containing allantoin (as known as Moogoo Udder 
Cream®) versus aqueous cream in reducing RISR, improving pain, itching and 
quality of life in this patient group. One group will receive Moogoo Udder Cream®. 
Another group will receive aqueous cream. Outcome measures will be collected 
using patient self-administered questionnaire, interviewer administered 
questionnaire and clinician assessment at commencement of radiotherapy, weekly 
during radiotherapy, and four weeks after the completion of radiotherapy. 
Discussion: 
Despite advances of radiologic advances and supportive care, RISR are still not 
well managed. There is a lack of efficacious interventions in managing RISR. While 
anecdotal evidence suggests that Moogoo Udder Cream® may be effective in 
managing RISR, research is needed to substantiate this claim. This paper presents 
the design of a double blind randomised controlled trial that will evaluate the effects 
of Moogoo Udder Cream® versus aqueous cream for managing in RISR in patients 
with cancer. 
Trial registration: ACTRN 12612000568819 
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Background 
Radiotherapy remains an essential treatment for patients with cancer and is 
associated with a number of short term and long term side effects [1]. One of these 
side effects includes radiation-induced skin reactions (RISR), also known as 
radiation dermatitis, which affects up to 90% of cancer patients receiving 
radiotherapy [2-4]. Approximately, 85% of these patients experience a moderate-to-
severe skin reaction [5, 6]. The reactions are the combined result of a decrease in 
functional stem cells, changes in the skin’s endothelial cells, inflammation, and skin 
cell necrosis and death of the skin [7]. Radiation-induced skin reactions are often 
characterised by oedema, erythema, changes in pigmentation, fibrosis and 
ulceration [8]. Signs and symptoms may include skin dryness, itching discomfort, 
pain, warmth, and burning [9]. Radiation-induced skin reactions have an impact on 
pain and quality of life in this patient group [10], and if severe, may necessitate 
changes to the patient’s radiation schedule [11]. Therefore, managing skin 
reactions is an important priority in caring for this patient group [9].  
 
The development of RISR may begin immediately, with increasing toxicity occurring 
at 2-3 weeks, with effects accumulating across the course of treatment, and may 
persist up to 4 weeks after treatment ends [4]. Other risk factors influencing RISR 
reported in the literature are both intrinsic or extrinsic [12]. The intrinsic factors are 
age, general health, ethnic origin, co-existing diseases, UV exposure, hormonal 
status [12] and genetic factors [13]. The extrinsic factors include the dose, volume, 
and number of fractions of radiation, radio-sensitizers, concurrent chemotherapy 
and the site of treatment [12]. A range of interventions are used for prophylaxis and 
management of these reactions. These interventions include (i) topical preparations 
(both steroidal and non-steroidal), (ii) dressings, (iii) systematic treatment such as 
amifostine, oral hydrolytic enzymes, pentoxifylline and zinc supplement, (iv) 
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alternating modes of radiation delivery. The latest published systematic review 
including 39 trials before 2008 reported that only topical corticosteroid agents, 
among other interventions mentioned above, were found to significantly reduce the 
severity of some RISR, but not the levels of pain and itching [5]. Further, it is not yet 
clear which corticosteroid is superior to other non-steroidal agents [5]. This 
systematic review, together with a number of other previous reviews concluded that 
the uses of these interventions are not yet supported by conclusive evidence and 
warrant further investigations [4, 5, 10, 14, 15]. Current evidence indicates that 
there is a paucity of conclusive evidence which can inform health professionals on 
effective skin management of RISR [16, 17].  
 
A natural oil-based emulsion, as known as Moogoo Udder Cream®, is a 
Queensland owned product that comprises allantoin, purified water, sweet almond 
oil, olive oil, rice bran oil, emulsifying wax, milk protein, aloe vera, vitamin E, 
glycerol caprylate, piroctone alamine and guarsilk. Anecdotal reports by patients 
with RISR and radiation oncologists in a number of Australian cancer centres 
suggest that Moogoo Udder Cream® may be effective in promoting healing, 
comfort, and pain relief.  This product is being increasingly used in some other 
Australian cancer centres in for managing RISR, however there is not yet empirical 
evidence supporting this claim. This study aims to investigate the effects of Moogoo 
Udder Cream® against aqueous cream (which is current standard of care) in 
patients with RISR. 
 
 
Objective of the study 
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The aim of this study is to assess the efficacy of Moogoo Udder Cream® against 
aqueous cream for managing RISR in patients with breast cancer/ lung cancer and 
head and neck cancer receiving radical radiotherapy.  
 
Methods and materials 
Design 
A double-blind randomised controlled trial design will be used in this study.  
 
Research questions 
1. Is there any difference in incidence of Grade 2 ,3 and 4 RISR between 
patients with breast, lung and head and neck cancers who receive Moogoo 
Udder Cream® and those who receive aqueous cream at week 5? 
2. Do patients with breast, lung and head and neck cancers who receive 
Moogoo Udder Cream® for their RISR have a different level of quality of life 
compared to those who receive aqueous cream at week 5? 
3. Do patients with breast, lung and head and neck cancers who receive 
Moogoo Udder Cream® for their RISR have a different level of pain 
compared to those who receive aqueous cream at week 5? 
4. Do patients with breast, lung and head and neck cancers who receive 
Moogoo Udder Cream® for their RISR have a different level of itching 
compared to those who receive aqueous cream at week 5? 
5. Is there any difference in time to grade 2, 3 and 4 of RISR between patients 
with breast, lung and head and neck cancers who receive Moogoo Udder 
Cream® and those who receive aqueous cream? 
6. Is there any difference in the clinical outcomes in all other time points 
assessed? 
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Sampling frame 
Participants in this study will all be patients receiving radical radiotherapy for lung 
cancer, breast cancer and head and neck cancer at the Royal Brisbane and 
Women’s Hospital (see table 1). A sample of consecutive eligible and consented 
patients will be recruited into the study.  
 
Baseline characteristics 
Baseline characteristics are demographic and clinical variables which include 
personal factors and radiotherapy factors (see table 2).  
 
Outcomes 
Primary outcome 
Severity of skin reaction (assessment by the clinician) 
The Common Terminology Criteria for Adverse Events (CTCAE- Version 4.0) will 
be used to assess the severity of RISR [18]. This instrument is well used and well 
validated in radiation oncology for assessing radiation dermatitis [19]. This 
assessment will be undertaken weekly by a research nurse with extensive clinical 
experience in radiation oncology on a weekly basis during their weekly progress 
evaluation clinic during their treatment period. This scoring system is widely used in 
practice and research. The research nurse will be instructed prior to the beginning 
of the study to score the worst toxicity present, at the time of assessment within the 
treatment field.  
 
Secondary outcomes 
Quality of life (skin specific) (self-administered by the patient) 
Skindex-16 is a 16-item self-administered survey instrument developed by Chren 
and her research team in 2001 to measure the effects of skin condition on quality of 
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life [20, 21]. Skindex-16 comprises three scales to assess patient emotion, 
symptoms and functioning. Item responses are standardized from 0 (no effect) to 
100 (maximal effect). The scale demonstrated good psychometric properties:  
reliability at 72 hours (r=0.68-0.90) and internal consistency (Cronbach’s Alpha = 
0.76-0.86). This tool has been increasing used in patients with skin toxicities 
resulted from their anti-cancer treatment [21-23]. Permission to use this tool has 
been granted by the author.  
 
Modified Brief Pain Inventory (self- administered by the patient) 
This study will use three measures from the Brief Pain Inventory (BPI), those of the 
average, best, and worst pain, and pain relief scores from the preceding seven 
days [24]. The participant will be asked to rate their pain level at the irradiated area. 
The time of interest of the original BPI is modified from “the past 24 hours” to “the 
past 7 days” for the specific purpose of this study. The BPI has been selected as it 
is a brief and easy tool for the assessment of pain within both the clinical and 
research settings. It has been well validated in both the chronic pain and cancer 
settings. The scale of 0 to 10 is simple for patients to use and reflects common 
clinical assessment of pain.  
 
Itching (self- administered by the patient) 
Itching will be scored on a numeric analogue scale of 0-10 in the treated skin (0= no 
itching at all), (10= itching as bad as you can imagine).  
 
Treatment interruptions 
Treatment interruptions due to severe skin reactions will be documented throughout 
the study (Yes/No). This decision is determined by the treating medical officers. 
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Adverse events 
Any adverse events will be reported by the investigators. Adverse events will 
include allergic reactions from the allocated treatment and will be assessed using 
the Common Toxicity Criteria for Adverse Events version 4.0. (CTCAE v4) [16]. 
 
 
Sample size 
A sample size of at least 81 in each arm would be required to detect a 20% 
difference in the skin reactions scores using a 2-sided significant level of 0.05 and a 
power of 80%. Assuming that approximately 5% will be lost to follow-up; an 
additional 5 in each group will be required so the final sample will require 172 
patients (86 per arm). All eligible patients will be approached consecutively. 
According to the local statistics of RBWH Cancer Care Services [25], 746 patients 
receive radical radiotherapy for breast cancer, lung cancer and head and neck 
cancer over a twelve-month period. Thus, the sample size proposed is achievable 
over a period of seven months.  
 
Randomisation 
Eligible and consenting patients will be randomly allocated to the intervention group 
to receive Moogoo Udder Cream®, or the control group to receive aqueous cream. 
 
Sequence generation 
Blocked randomisation will be performed, with a block size of six, by a computer 
generated random number list prepared by an investigator who has no clinical 
involvement in the trial. Stratification by irradiated sites (breast, lung or head and 
neck), BMI categories (underweight <18.50, normal = 18.50-24.99, overweight =25-
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29.9, obesity>30) and smoking status (smoking and non-smoking) will be carried 
out. 
 
Allocation concealment and blinding  
After the research nurse has obtained the patient’s consent. The research nurse will 
then allocate participants to either receive Cream 1 (Group 1), or receive Cream 2 
(Group 2) according to the generated sequence. This proposed study is a double-
blind study. Blinding will be accomplished by not disclosing to the research nurse, 
medical officers, radiation therapists, nurses or participants which preparation used 
for skin treatment for each of the participants.  
 
Both topical preparations (Moogoo Udder Cream® and aqueous cream) are white 
in colour, have similar consistency, and have no distinct odour. There are no other 
differentiating features. Both topical preparations will be provided and coded as 
Cream 1 or Cream 2 by the manufacturer in identical containers. The manufacturer 
will only disclose what Cream 1 and Cream 2 are at the completion of data 
collection. Subsequently, baseline data will be collected.  
 
Procedures 
During the first visit, the doctor or nurse will introduce the study to eligible patients. 
If the patient is interested in the study; the research nurse will approach the patient 
and explain to him/her details of the study. At this time, the information sheet will be 
provided and informed consent will be obtained.  
 
Any participant with known allergy to any ingredient of Moogoo Udder Cream® or 
the aqeuous cream will receive a patch test to determine a potential reaction with 
either cream. The patch test entails application of a small amount of the Moogoo 
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Udder Cream® and the aqueous cream to two different sites distal to the irradiated 
area. This is reviewed after 24 hours for any reaction (a 24 hour timeframe was 
advised by literature and the RBWH Dermatology specialists). If after 24 hours, the 
patient is found to have a reaction to either cream, they will not be randomised onto 
the trial. 
 
Patients allocated to Group one will receive Cream 1. Group two will receive Cream 
2. Patients will be asked to start topical application of their allocated cream on the 
area of skin being irradiated at the onset of radiotherapy, twice a day or more as 
needed depending on the occurrence of RISR and pain, until the skin reaction 
subsides. The amount of cream dispensed to each patient will be recorded 
throughout treatment. If moist desquamation occurs, the topical preparation will be 
discontinued in the area of skin breakdown and dressings will be applied until the 
wound heals as per standard care. Patients will be asked to still continue with the 
topical preparation onto irradiated area that has no breakdown. All participants are 
given written instructions on how to apply the allocated treatment (see Fig 1). 
 
All other skin care advice given to both groups of patients will be the same, as per 
the local policy of the Royal Brisbane and Women’s Hospital. All patients will be 
advised to  
- wear loose, comfortable cotton clothing in the area being treated 
- use a gentle detergent 
- not wear an under wire bra if they are treated for breast cancer 
- avoid temperature extremes and use lukewarm water to wash 
- not use hot or ice packs 
- not use a harsh soap or shampoo on irradiated skin 
- keep irradiated skin dry 
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- air skin 2-3 times a day 
- not use a blade razor on irradiated skin 
- not expose irradiated skin to the sun 
- not rub or scratch irradiated skin; patients may apply cool moist washers if 
skin feels itchy or hot 
- pat skin dry with a soft towel after washing or air dry 
- not use any tapes, band aids, or dressing unless advised by their clinicians. 
- not use other topical preparations in the treatment area 
- rinse off immediately in fresh water if swimming in a pool or salt water (if the 
skin is intact) 
 
Discontinuation 
If discontinuation of study skin care products occurs due to allergy (or another 
patient reason), substitution of alternative creams is at the treating clinician’s 
discretion. Application of both study skin products should cease, as un-blinding for 
an individual may reveal product types for future patients even though the labelling 
of the products as 1 or 2 is randomised and the products are very similar in 
appearance. A variety of other skin products are available so it is unnecessary to 
continue with either of the study products.  
 
Discontinuation of the study creams does not constitute withdrawal from the study 
and scheduled assessments should continue as described in this protocol.  
 
Data Collection 
Table 3 outlines the measures used in this study. At baseline and weekly during 
treatment, data will be collected when patients are in the radiation oncology 
department. At completion of radiotherapy, patients will be given the diaries to 
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complete at home at week 1, week 2 and week 3 post-treatment. The research 
nurse will contact the patient via telephone to remind them to complete the diaries. 
At week 4 post-treatment, all patients who have completed their treatments will 
return to the radiation oncology department for a routine medical review. At this 
time, they will be asked to complete the final questionnaire and have the severity of 
their skin reaction assessed by the research nurse.   
 
Data analysis 
Patient characteristics between arms will be compared using the chi-square test for 
discrete variables and the t-test for continuous variables. Acute reactions will be 
evaluated using Kaplan-Meier actuarial plots (time to event) with the log-rank test 
for significance. Grade reaction plots at the particular time points (weeks) will be 
plotted and compared with 95% confidence intervals for both arms. Uni-variate 
regression models will determine the significance of factors to be included in the 
multivariate regression model. A generalized linear interactive modelling package 
(GLIM4) will be used. 
 
Discussion 
Despite advances of radiologic advances and supportive care, RISR are still not 
well managed. There is a lack of efficacious interventions in managing RISR. While 
anecdotal evidence suggests that Moogoo Udder Cream® may be effective in 
managing RISR, research is needed to substantiate this claim. This paper presents 
the design of a double blind randomised controlled trial that will evaluate the effects 
of Moogoo Udder Cream® versus aqueous cream for managing in RISR in patients 
with cancer. 
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Table 1. Recruitment criteria for this study 
Recruitment criteria 
Inclusion criteria Exclusion criteria 
 Age >18 years 
 Patients who have a definitive 
diagnosis of breast cancer, lung 
cancer or head and neck cancer 
 Patients who are receiving 
radiotherapy (>50 Gy) either as 
primary treatment or postoperative 
treatment to their chest, breast or head 
and neck.  
 
 Patients who are unable to consent 
 Patients with pre-existing skin rash, 
ulceration or open wound in the 
treatment area 
 Patients with known allergic and 
other systemic skin diseases even 
not directly affecting irradiated fields. 
 Patients with any known allergic 
reactions towards any ingredient of 
either the Moogoo Udder Cream® or 
the aqueous cream and failed the 
patch test. 
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Table 2. Summary of baseline characteristics and data collection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Independent variables Data collection 
Personal factors 
 
 
 
 
 
 
 
 
Age 
Gender 
Ethnicity 
Stage of cancer (Staging, nodal involvement) 
Comorbidity 
Prior chemotherapy/ radiotherapy 
Concurrent chemotherapy/ biotherapy (e.g. 
monoclonal anti-bodies) 
Body mass index 
Smoking 
Cup-size (breast and axilla) 
Radiotherapy factors 
 
Daily dose (Gy/fraction) 
Planning target volume (cm3) 
Total dose to region of interest 
Site of radiotherapy 
Radiation technique (External beam via 
Tomotherapy/ Linear accelerator) 
Boost (Yes or no) 
Number of boost treatments 
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Table 3. Table of study measure 
Measures Administered 
by 
Baseline 
(i.e. Day –7 
to Day 0 of 
radiation 
treatment) 
Weekly during 
treatment (i.e. 
Day 5, 10, 15, 
20, 25, 30 of 
radiation 
treatment) 
Week 1, 
week 2 and 
week 3 post 
treatment 
(i.e. Day 5, 
10, 15 post 
radiation 
treatment) 
4 weeks after 
radiation 
treatment 
 
Review 
appointment 
(Face to face) 
Personal factors 
(see Table 1) 
Research 
nurse 
*    
Radiotherapy 
factors (see 
Table 1) 
 
Research 
nurse 
*    
CTCAE Research 
nurse 
* *  * 
Modified Brief 
Pain Inventory 
Patient * * * * 
Itching Patient * * * * 
Skindex-16 Patient * * * * 
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Instructions for applying the cream on your irradiated skin 
 
 On the first visit (Day 1 of the treatment, ie week 1 of trial), the nurse will 
show you how to apply creams making sure that no areas are missed. Use a 
thin film, it doesn’t need to be a thick application. You can apply the cream 
twice a day or more as needed, usually straight after a shower. The 
creams are to be applied everyday until 4 weeks after completing your 
radiotherapy. 
 
 Please bring the creams along with you each week when we do the skin 
reviews (every Friday). We will have a look at how much cream is left to see 
if more cream is needed.  
 
 You are advised not to use other creams, unless if it is instructed by your 
doctor. Please tell us if you are using any other creams. 
 
Fig 1. Instructions for cream application 
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